Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
European Brain Research Institute (Ebri) R Levi Montalcini maintains a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 1 pending office action. This single action is assigned to 1 distinct examiner and is being processed in 1 distinct art unit. This reflects a very specific and limited scope of current prosecution activity. For a practitioner, this means that the prosecution strategy is entirely dependent on the interaction with this 1 distinct examiner and the specific standards of the 1 distinct art unit.
The busiest examiner for this portfolio is MACFARLANE, STACEY NEE, who is currently managing 1 busiest examiner pending action. Since the total number of pending office actions is 1, MACFARLANE, STACEY NEE is the sole official responsible for the company's current patent review. The involvement of only 1 distinct art unit further suggests that the pending matter falls within a specific technical niche of the Biotechnology & Pharmaceuticals field. This concentration requires a targeted approach to satisfy the examiner's requirements, as the outcome of the 1 pending office action will define the current success of the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MACFARLANE, STACEY NEE | 1 | 53.7% | +39.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18698716 | METHOD FOR THE EARLY DIAGNOSIS OF NEURODEGENERATIVE DISEASES BY MEANS OF QUANTIFICATION OF PRONGF AND DERIVED FORMS THEREOF | MACFARLANE, STACEY NEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18698716 | METHOD FOR THE EARLY DIAGNOSIS OF NEURODEGENERATIVE DISEASES BY MEANS OF QUANTIFICATION OF PRONGF AND DERIVED FORMS THEREOF | MACFARLANE, STACEY NEE | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18698716 | METHOD FOR THE EARLY DIAGNOSIS OF NEURODEGENERATIVE DISEASES BY MEANS OF QUANTIFICATION OF PRONGF AND DERIVED FORMS THEREOF | MACFARLANE, STACEY NEE | 1675 | §101§103§112 | Non-Final OA | — | Pending | Apr 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEuropean Brain Research Institute (Ebri) R Levi Montalcini has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Stacey Nee Macfarlane has the most, with 1 of European Brain Research Institute (Ebri) R Levi Montalcini's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.